Local intra-arterial fibrinolysis of thromboemboli occurring during XXXX with recombinant tissue plasminogen activator.

@entity1 @entity4798 @entity1188 @entity1031 @entity1779 @entity432 @entity583 @entity12870 @entity715
BACKGROUND AND PURPOSE: There is a lack of systematic data regarding @entity432 ( @entity432 ) of thromboemboli occurring during @entity12870 with the use of recombinant tissue plasminogen activator (rtPA). We report our technique for treating @entity432 of intracerebral thromboemboli occurring during @entity12870 . METHODS: Nine of 723 @entity1 (1.2%) who underwent @entity12870 during the period from January 1997 to September 2002 suffered @entity1031 . These @entity1 were treated by @entity432 with a maximum dose of 0.9 mg rtPA per kilogram body weight. Recanalization was categorized as successful (Thrombolysis in @entity583 [TIMI] grade 2 or 3) versus unsuccessful (TIMI grade 0 or 1), and clinical outcome was categorized as independent (Rankin Scale score 0 to 2) versus dependent or dead (Rankin Scale score 3 to 6). RESULTS: The minimum time between @entity715 detection and beginning of @entity432 was 10 minutes, and the maximum time was 90 minutes. Successful recanalization was achieved in 4 of 9 @entity1 (44%). All 9 @entity1 suffered cerebral @entity1188 , and none of the @entity1 sustained @entity1779 . Two @entity1 (22%) died from malignant @entity4798 . Four @entity1 (44%) remained moderately disabled, and 3 @entity1 (33%) were severely disabled 3 months after @entity432 . CONCLUSIONS: Although we used relatively high doses of rtPA, the recanalization rates and clinical outcome of @entity432 in our @entity1 were not satisfactory. Strategies for the prevention of thromboemboli during @entity12870 must be improved, and novel fibrinolytic or thrombolytic techniques should be developed.
